
NYSTATIN- nystatin suspension Taro Pharmaceuticals U.S.A., Inc.

Nystatin Oral Suspension, USP

Rx Only

DESCRIPTION

Nystatin is an antimycotic polyene antibiotic obtained from *Streptomyces noursei*. Structural formula:



Nystatin Oral Suspension, for oral administration, is cherry/mint flavored, containing 100,000 USP Nystatin Units per mL. Inactive ingredients: alcohol (\leq 1% v/v), benzaldehyde, edetate calcium disodium, flavors, glycerin, magnesium aluminum silicate, methylparaben, propylparaben, purified water, saccharin sodium, sodium citrate, sucrose (49.8% w/v), xanthan gum.

CLINICAL PHARMACOLOGY

Pharmacokinetics

Gastrointestinal absorption of nystatin is insignificant. Most orally administered nystatin is passed unchanged in the stool. In patients with renal insufficiency receiving oral therapy with conventional dosage forms, significant plasma concentrations of nystatin may occasionally occur.

Microbiology

Nystatin is both fungistatic and fungicidal *in vitro*against a wide variety of yeasts and yeast-like fungi. *Candida albicans*demonstrates no significant resistance to nystatin *in vitro*on repeated subculture in increasing levels of nystatin; other *Candida*species become quite resistant. Generally, resistance does not develop *in vivo*. Nystatin acts by

binding to sterols in the cell membrane of susceptible *Candida*species with a resultant change in membrane permeability allowing leakage of intracellular components. Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.

INDICATIONS AND USAGE

Nystatin Oral Suspension is indicated for the treatment of candidiasis in the oral cavity.

CONTRAINDICATIONS

The preparation is contraindicated in patients with a history of hypersensitivity to any of its components.

PRECAUTIONS

General

This medication is not to be used for the treatment of systemic mycoses. Discontinue treatment if sensitization or irritation is reported during use.

Carcinogenesis, Mutagenesis, Impairment of Fertility

No long-term animal studies have been performed to evaluate carcinogenic potential. There also have been no studies to determine mutagenicity or whether this medication affects fertility in males or females.

Pregnancy

Teratogenic Effects Category C

Animal reproduction studies have not been conducted with nystatin oral suspension. It is also not known whether nystatin oral suspension can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Nystatin oral suspension should be given to a pregnant woman only if clearly needed.

Nursing Mothers

It is not known whether nystatin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when nystatin is administered to a nursing woman.

Pediatric Use

See **DOSAGE AND ADMINISTRATION**.

ADVERSE REACTIONS

Nystatin is well tolerated even with prolonged therapy. Oral irritation and sensitization have been reported. (See **PRECAUTIONS: General**).

Gastrointestinal: Diarrhea (including one case of bloody diarrhea), nausea, vomiting,

gastrointestinal upset/disturbances.

*Dermatologic:*Rash, including urticaria has been reported rarely. Stevens-Johnson syndrome has been reported very rarely.

*Other:*Tachycardia, bronchospasm, facial swelling, and non-specific myalgia have also been rarely reported.

OVERDOSAGE

Oral doses of nystatin in excess of five million units daily have caused nausea and gastrointestinal upset. There have been no reports of serious toxic effects of superinfections (See **CLINICAL PHARMACOLOGY, Pharmacokinetics**).

DOSAGE AND ADMINISTRATION

INFANTS

2 mL (200,000 units) four times daily (in infants and young children, use dropper to place one-half of dose in each side of mouth and avoid feeding for 5 to 10 minutes).

NOTE:Limited clinical studies in premature and low birth weight infants indicate that 1 mL four times daily is effective.

CHILDREN AND ADULTS

4 to 6 mL (400,000 to 600,000 units) four times daily (one-half of dose in each side of mouth). The preparation should be retained in the mouth as long as possible before swallowing.

Continue treatment for at least 48 hours after perioral symptoms have disappeared and cultures demonstrate eradication of *Candida albicans*.

HOW SUPPLIED

Nystatin Oral Suspension, USP, 100,000 USP Nystatin U/mL, is available as a cherry-mint flavored, light creamy yellow, ready-to-use suspension in:

2 fl oz (60 mL) bottles with 0.5 mL, 1 mL, 1.5 mL, 2 mL calibrated dropper NDC 51672-4117-4 1 Pint (473 mL) bottles NDC 51672-4117-9 1 Gallon (3785 mL) bottles (For repackaging only) NDC 51672-4117-0

SHAKE WELL BEFORE USING

Storage

Store at 20° to 25°C (68° to 77°F)[see USP Controlled Room Temperature]. Protect from freezing.

PHARMACIST:Dispense in a tight, light-resistant container as defined in USP.

Manufactured by: Taro Pharmaceutical Industries Ltd. Haifa Bay, Israel 2624761 Distributed by: **Taro Pharmaceuticals U.S.A.**, Inc. Hawthorne, N.Y. 10532

Revised: May 2019 70564-0519-2

PRINCIPAL DISPLAY PANEL - 60 mL Bottle Label

NDC 51672-4117-4

2 fl oz (60 mL)

Nystatin

Oral Suspension USP,

100,000 units/mL

SHAKE WELL BEFORE USING

CHERRY/MINT FLAVORED

TARO

Rx only



NYSTATIN nystatin suspension								
Product Information								
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:51672-4117					
Route of Administration	ORAL							

		lient/Acti	ve Moiety					
		Ingred	ient Name		Basis of	Strength		Strength
NY	(STATIN (UNII: E	3DF101C72E	(NYSTATIN - UNII:BDI	F101C72E)	NYSTATIN		10000	0 [USP'U] in 1 m
In	active Ingr	edients						
		culcilly	Ingredient	Name				Strength
ΔΙ	COHOL (UNII: 3	K9928\/90M)	ingreatent	Name				Strength
			M (UNII: 25IH6R4SGF)					
	YCERIN (UNII: F							
MA	AGNESIUM ALU	MINUM SILI	CATE (UNII: 6M3P64V	ONC)				
ME	THYLPARABE	I (UNII: A2180	7HI9T)					
PR	OPYLPARABEN	(UNII: Z8IX2	SC1OH)					
W	ATER (UNII: 059	QF0KO0R)						
SA	CCHARIN SOD	IUM (UNII: SI	38Z UX40TY)					
50	DIUM CITRATE	E, UNSPECIF	IED FORM (UNII: 1Q	73Q2JULR)				
	CROSE (UNII: C							
XA	NTHAN GUM (L	JNII: TTV12P4	NEE)					
	oduct Chai		cs					
Color			yellow (light creamy yellow)					
		yellow (l	ght creamy yellow)			Score		
Sh	ape					Size		
Sh Fla	ape avor		ght creamy yellow) (Cherry-mint flavored)			ode	
Sh Fla	ape)		Size	ode	
Sh Fla	ape avor)		Size	ode	
Sh Fla Co	ape avor)		Size	ode	
Sh Fla Co Pa	ape avor ontains				Mar	Size		Marketing End Date
Sh Fla Co Pa #	ape avor ontains ackaging		(Cherry-mint flavored Package Descr			Size Imprint C		
Sh Fla Co Pa #	ape avor ontains ackaging Item Code NDC:51672-	CHERRY 1 in 1 CART	(Cherry-mint flavored Package Descr DN BOTTLE, DROPPER; Ty	iption		Size Imprint C Meting Sta Date		
Sh Fla Co Pa 1	ape avor ontains ackaging Item Code NDC:51672-	CHERRY 1 in 1 CART 60 mL in 1 I Combination	(Cherry-mint flavored Package Descr DN BOTTLE, DROPPER; Ty	iption pe 0: Not a	02/29	Size Imprint C Meting Sta Date		
Sh Fla Co Pa # 1 1	hape avor ontains ackaging Item Code NDC:51672- 4117-4	CHERRY CHERRY	(Cherry-mint flavored Package Descr DN BOTTLE, DROPPER; Ty Product	iption pe 0: Not a a Combination	02/29	Size Imprint C Mate Date		
Sh Fla Co Pa # 1 1 2	hape avor ontains ackaging item Code NDC:51672- 4117-4	CHERRY CHERRY	(Cherry-mint flavored Package Descr DN BOTTLE, DROPPER; Ty Product BOTTLE; Type 0: Not	iption pe 0: Not a a Combination	02/29	Size Imprint C Mate V1988		
Sh Fla Co Pa # 1 1 2 3	hape avor ontains ackaging item Code NDC:51672- 4117-4	CHERRY CHERRY	(Cherry-mint flavored Package Descr DN BOTTLE, DROPPER; Ty Product BOTTLE; Type 0: Not 1 BOTTLE; Type 0: Not	iption pe 0: Not a a Combination	02/29	Size Imprint C Mate V1988		
Sh Fla Co Pa # 1 1 2 3	hape avor ontains ackaging item Code NDC:51672- 4117-4	CHERRY CHERRY 1 in 1 CART 60 mL in 1 l Combination 473 mL in 1 Product 3785 mL in Product Inform	(Cherry-mint flavored Package Descr DN BOTTLE, DROPPER; Ty Product BOTTLE; Type 0: Not 1 BOTTLE; Type 0: Not	iption pe 0: Not a a Combination ot a Combinatio	02/29 02/29 n 02/29	Size Imprint C Mate V1988	art I	

Labeler - Taro Pharmaceuticals U.S.A., Inc. (145186370)

Establishment								
Name	Address	ID/FEI	Business Operations					
Taro Pharmaceutical Industries Ltd.		600072078	manufacture(51672-4117)					

Revised: 12/2024

Taro Pharmaceuticals U.S.A., Inc.